CD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 –

CD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 –

CD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 –

DUBLIN–(BUSINESS WIRE)–The “CD47 Targeting Therapeutics Market by Target Disease Indication, Type of Molecule Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035” report has been added to’s offering.

The report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of CD47 targeting therapeutics in the healthcare industry, over the next 15 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

Amongst other elements, the report features:

  • A detailed overview of the current market landscape of CD47 targeting therapeutics, along with information on several relevant parameters, such as phase of development, target disease indication(s), therapeutic area, target molecule, type of molecule, type of therapy, type of biologic, route of administration and special drug designation awarded. In addition, it presents details of the companies engaged in the development of CD47 targeting therapeutics, as well as information on their year of establishment, company size and location of respective headquarters.
  • Profiles of key players engaged in the development of CD47 targeting therapeutics. Each profile features a brief overview of the company, details on its drug candidates, financial information, recent developments and informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical trials of various CD47 targeting therapeutics, based on several relevant parameters, such as trial registration year, number of patients enrolled, gender of patients enrolled, trial phase, recruitment status and study design, leading sponsors/collaborators, most active players, type of organization, popular therapeutic areas, and regional distribution of trials.
  • A detailed review of close to 600 peer-reviewed, scientific articles related to research on CD47 targeting therapies over the past few years, based on several relevant parameters, such as year of publication, type of publication, therapeutic area, target indication and key journals.
  • An analysis of the recent partnerships inked between various players engaged in the development of CD47 targeting therapies, during the period 2016-2021, based on several relevant parameters, such as number of partnership instances, type of partnerships, regional distribution and most active players.
  • A detailed analysis of various investments, such as venture capital financing, debt financing, grants/awards, capital raised from IPOs and subsequent offerings that were undertaken by companies engaged in this domain, during the period 2016-2021.
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 22 matrix assessing the relative experience of KOLs shortlisted based on their contributions in this domain, and a schematic world map representation, indicating the geographical location of eminent scientists/researchers engaged in the development of CD47-based therapies.
  • An analysis of the companies engaged within this domain, featuring a 3-D bubble chart analysis of different peer groups, based on various parameters, such as pipeline strength, portfolio diversity and portfolio strength
  • An analysis of big pharma players engaged in this domain, featuring a wind rose chart based on several relevant parameters, such as number of therapeutics under development, phase of development, line of therapy, number of indications targeted and years of experience.
  • An analysis of the start-ups engaged in the development of CD47 based therapeutics.

Key Questions Answered

  • Who are the leading players engaged in the development of CD47 targeting therapeutics?
  • Which are the key drugs being developed across early and late stages of development?
  • Which companies are actively involved in conducting clinical trials for their therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors in this domain?
  • Who are the key opinion leaders/experts in this field?
  • What are the evolving social media trends related to CD47 targeting therapeutics?
  • What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past?
  • How is the current and future opportunity likely to be distributed across key market segments?

Select Companies Mentioned

  • AbbVie
  • Abpro
  • Acerta Pharma
  • Adage Capital Management
  • Akeso
  • Alector
  • ALX Oncology
  • Apmonia Therapeutics
  • Arch Oncology
  • Ascentage Pharma
  • Avego Healthcare Capital
  • Avidity Partners
  • Bio-Thera Solutions
  • BliNK Biomedical
  • Boehringer Ingelheim
  • Boxer Capital
  • Bristol-Myers-Squibb
  • BVF Partners
  • Chinook Therapeutics
  • Clarus Ventures
  • Conjupro Biotherapeutics
  • EcoR1 Capital
  • Eli Lilly
  • Elpiscience
  • Emerson Collective
  • EMulate Therapeutics
  • EpicentRx
  • Flerie Invest
  • Foresite Capital
  • Forty Seven
  • Genentech
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • GV
  • Hadasit Bio Holdings
  • Hanmi Pharmaceuticals
  • Hatteras Venture Partners
  • Ichnos Sciences
  • I-Mab Biopharma
  • Innovent Biologics
  • K2 HealthVentures
  • KAHR Medical
  • Lightstone Ventures
  • Lilly Asia Ventures (LAV)
  • Logos Capital
  • Lonza
  • LYFE Capital
  • Lynkcell
  • MacroGenics
  • Merck
  • Morphiex Biotherapeutics
  • Mountain Pacific Venture
  • Novimmune
  • Novo Nordisk
  • Ono Pharmaceutical
  • Oriella
  • Partner Fund Management
  • Pavilion Capital
  • Peregrine Ventures
  • Pfizer
  • PharmAbcine
  • Piper Sandler
  • Point72 Asset Management
  • QLSF Biotherapeutics
  • Redmile Group
  • RiverVest Venture Partners
  • Roche
  • Roche Venture Fund
  • Saiyuan
  • Samsung BioLogics
  • Sanquin
  • SATT Nord
  • Shattuck Labs
  • Shavit Capital
  • Sutter Hill Ventures
  • Synthon Biopharmaceuticals
  • Tallac Therapeutics
  • TG Therapeutics
  • Trillium Therapeutics
  • venBio
  • Vivo Capital
  • Vivoryon Therapeutics
  • Waterstone Hanxbio
  • Zai Lab
  • Zymeworks

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900